$6.69
0.89% yesterday
Nasdaq, Jun 12, 10:07 pm CET
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Day One Biopharmaceuticals Inc Stock price

$6.69
+0.11 1.67% 1M
-6.12 47.78% 6M
-5.98 47.20% YTD
-6.31 48.54% 1Y
+5.64 537.14% 5Y
+5.64 537.14% 10Y
+5.64 537.14% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.06 0.89%
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Key metrics

Market capitalization $678.11m
Enterprise Value $205.09m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.27
P/S ratio (TTM) P/S ratio 4.19
P/B ratio (TTM) P/B ratio 1.41
Revenue (TTM) Revenue $161.92m
EBIT (operating result TTM) EBIT $-83.57m
Free Cash Flow (TTM) Free Cash Flow $-110.47m
Cash position $473.02m
EPS (TTM) EPS $-0.66
P/E forward negative
P/S forward 4.47
EV/Sales forward 1.35
Short interest 27.24%
Show more

Is Day One Biopharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Day One Biopharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

Buy
89%
Hold
11%

Financial data from Day One Biopharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
162 162
-
100%
- Direct Costs 8.16 8.16
-
5%
154 154
-
95%
- Selling and Administrative Expenses 118 118
41% 41%
73%
- Research and Development Expense 227 227
59% 59%
140%
-81 -81
64% 64%
-50%
- Depreciation and Amortization 2.90 2.90
5,700% 5,700%
2%
EBIT (Operating Income) EBIT -84 -84
63% 63%
-52%
Net Profit -69 -69
67% 67%
-43%

In millions USD.

Don't miss a Thing! We will send you all news about Day One Biopharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Day One Biopharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
3 days ago
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One
Neutral
Seeking Alpha
8 days ago
DAWN reported modest Q1'25 sales growth vs Q4'24, and the reaction of the stock has unsurprisingly been muted. Upcoming Q2'25 earnings are pivotal: confirmation of accelerating growth could spark upside, while continued sluggishness risks further stock stagnation or decline. Potential European approval for Ojemda and phase 1 data from a trial of DAY-301 represent other catalysts ahead, but like...
Neutral
Seeking Alpha
about one month ago
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy Bender - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Charles York - Chief Operating & Financial Officer Elly Barry - Chief Medical Officer Conference Call Participants Tara B...
More Day One Biopharmaceuticals Inc News

Company Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeremy Bender
Employees 169
Founded 2018
Website dayonebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today